Cancer Targeted Gene Panel Lung with PD-L1 (DAKO) Test
At DNA Labs UAE, we offer the Cancer Targeted Gene Panel Lung with PD-L1 (DAKO) Test. This molecular diagnostic test is designed to identify genetic mutations and alterations in lung cancer cells. By targeting specific genes involved in lung cancer development and the PD-L1 protein, this test provides valuable information for personalized treatment planning.
Test Components
- ALK1
- ROS1
- MET amplification
- MET mutation
- KRAS
- BRAF
- ERBB2
- EGFR
- PDL-1 (Dako)
Price
AED 5400.0
Sample Condition
Submit a formalin-fixed paraffin-embedded tissue block. Ship at room temperature. Provide a copy of the Histopathology report, site of biopsy, and clinical history. A duly filled NGS Test Requisition Form is mandatory.
Report Delivery
Sample by 1st/16th of every month; Report 15th/30th of the same month
Method
IHC, FISH, NGS
Test Type
Cancer
Doctor
Oncologist
Test Department
Molecular Diagnostics
Pre Test Information
Provide a copy of the Histopathology report, site of biopsy, and clinical history. A duly filled NGS Test Requisition Form is mandatory.
Test Details
The Cancer Targeted Gene Panel: Lung with PD-L1 (DAKO) test is a molecular diagnostic test used to identify genetic mutations and alterations in lung cancer cells. This test specifically targets genes that are known to be involved in lung cancer development and progression, as well as the PD-L1 protein, which is a key target for immunotherapy treatments.
The test is performed on a sample of lung cancer tissue obtained through biopsy or surgery. The tissue is analyzed using advanced genomic sequencing technologies to identify specific mutations and alterations in the DNA of cancer cells.
The results of the test can help guide treatment decisions, as certain mutations may be targeted by specific therapies or immunotherapies. The PD-L1 protein is also analyzed as part of this test, as it is an important biomarker for predicting response to immunotherapy. PD-L1 is expressed on the surface of cancer cells and interacts with immune cells to suppress the immune response. Immunotherapy drugs such as checkpoint inhibitors target the PD-L1 protein to help activate the immune system and attack cancer cells.
Overall, the Cancer Targeted Gene Panel: Lung with PD-L1 (DAKO) test is a valuable tool for personalized treatment planning for patients with lung cancer, as it provides important information about the genetic makeup of their cancer cells and their potential response to specific therapies.
| Test Name | CANCER TARGETED GENE PANEL LUNG WITH PDL-1 DAKO Test |
|---|---|
| Components | *ALK1 *ROS1 *MET amplification *MET mutation *KRAS *BRAF *ERBB2 *EGFR *PDL-1 (Dako) |
| Price | 5400.0 AED |
| Sample Condition | Submit Formalin fixed paraffin embedded tissue block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. Duly filled NGS Test Requisition Formis mandatory. |
| Report Delivery | Sample by 1st/16th of every month; Report 15th/30th of same month |
| Method | IHC, FISH, NGS |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | Provide a copy of the Histopathology report, Site of biopsy and Clinical history. Duly filled NGS Test Requisition Formis mandatory. |
| Test Details | The Cancer Targeted Gene Panel: Lung with PD-L1 (DAKO) test is a molecular diagnostic test used to identify genetic mutations and alterations in lung cancer cells. This test specifically targets genes that are known to be involved in lung cancer development and progression, as well as the PD-L1 protein, which is a key target for immunotherapy treatments. The test is performed on a sample of lung cancer tissue obtained through biopsy or surgery. The tissue is analyzed using advanced genomic sequencing technologies to identify specific mutations and alterations in the DNA of cancer cells. The results of the test can help guide treatment decisions, as certain mutations may be targeted by specific therapies or immunotherapies. The PD-L1 protein is also analyzed as part of this test, as it is an important biomarker for predicting response to immunotherapy. PD-L1 is expressed on the surface of cancer cells and interacts with immune cells to suppress the immune response. Immunotherapy drugs such as checkpoint inhibitors target the PD-L1 protein to help activate the immune system and attack cancer cells. Overall, the Cancer Targeted Gene Panel: Lung with PD-L1 (DAKO) test is a valuable tool for personalized treatment planning for patients with lung cancer, as it provides important information about the genetic makeup of their cancer cells and their potential response to specific therapies. |
